AR114110A1 - Anticuerpo anti-trka - Google Patents

Anticuerpo anti-trka

Info

Publication number
AR114110A1
AR114110A1 ARP190100363A ARP190100363A AR114110A1 AR 114110 A1 AR114110 A1 AR 114110A1 AR P190100363 A ARP190100363 A AR P190100363A AR P190100363 A ARP190100363 A AR P190100363A AR 114110 A1 AR114110 A1 AR 114110A1
Authority
AR
Argentina
Prior art keywords
pain
antibodies
trka antibody
trka
treatment
Prior art date
Application number
ARP190100363A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR114110A1 publication Critical patent/AR114110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Anticuerpos contra el receptor tropomiosina quinasa (TrkA), composiciones que incluyen tales anticuerpos y métodos de uso de tales anticuerpos para el tratamiento del dolor, que incluye el dolor posquirúrgico, el dolor por artritis reumatoide, el dolor neuropático y el dolor por osteoartritis.
ARP190100363A 2018-02-28 2019-02-14 Anticuerpo anti-trka AR114110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862636207P 2018-02-28 2018-02-28

Publications (1)

Publication Number Publication Date
AR114110A1 true AR114110A1 (es) 2020-07-22

Family

ID=65686081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100363A AR114110A1 (es) 2018-02-28 2019-02-14 Anticuerpo anti-trka

Country Status (7)

Country Link
US (1) US10618974B2 (es)
EP (1) EP3759138A1 (es)
JP (1) JP7017641B2 (es)
CN (1) CN111788230B (es)
AR (1) AR114110A1 (es)
TW (1) TWI702233B (es)
WO (1) WO2019168730A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
CN112961244B (zh) * 2021-02-28 2023-08-29 熙源安健医药（上海）有限公司 抗TrkA抗体或其抗原结合片段、其制备方法和应用
WO2023125490A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Suzhou) Limited TrkA ANTIBODY AND APPLICATION THEREOF

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471205A1 (en) 1990-08-15 1992-02-19 E.R. SQUIBB & SONS, INC. Monoclonal antibodies which bind TRK proto-oncogene protein
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US20040058416A1 (en) 1994-03-18 2004-03-25 Presta Leonard G. Human trk receptors and neurotrophic factor inhibitors
NZ501161A (en) 1994-03-18 2001-03-30 Genentech Inc Chimeric human trkA-IgG polypeptides which bind to human nerve growth factor.
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US20020169154A1 (en) 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
CN102746399B (zh) 2002-12-24 2016-03-02 里纳特神经系统学公司 抗ngf抗体及其使用方法
WO2005019266A2 (en) 2003-07-15 2005-03-03 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US20060058250A1 (en) 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20060275797A1 (en) 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders
AU2014277649A1 (en) 2005-06-07 2015-01-22 Abbott Research B.V Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
EP1933714B1 (en) 2005-09-21 2020-03-18 The Regents of The University of California Systems and compositions for local imaging and treatment of pain
ITRM20060367A1 (it) 2006-07-13 2008-01-14 Lay Line Genomics Spa Muteine del hngf usi terapeutici e composizioni farmaceutiche
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
US8144893B2 (en) 2007-07-26 2012-03-27 Sherman Kenneth N Mobile microphone
WO2009036068A2 (en) 2007-09-14 2009-03-19 Emory University Gambogic amine, a selective trka agonist with neuroprotective activity
KR101782857B1 (ko) 2008-02-04 2017-09-28 레이 라인 지노믹스 에스.피.에이. 항―ｔｒｋａ 항체 및 이의 유도체
WO2012009640A2 (en) 2010-07-16 2012-01-19 The Ohio State University B cell depletion for central nervous system injuries and methods and uses thereof
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
JP2012201621A (ja) 2011-03-24 2012-10-22 Univ Of Fukui ＴｒｋＡを阻害するペプチド化合物及びその用途
WO2013026021A2 (en) 2011-08-18 2013-02-21 Buck Institute For Research On Aging Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
EA201492163A1 (ru) 2012-06-08 2015-08-31 Гленмарк Фармасьютикалс С.А. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
FR3025717A1 (fr) 2014-09-16 2016-03-18 Univ Lille Sciences Tech Utilisation conjointe d'un inhibiteur de trka et d'un inhibiteur de epha2 pour une utilisation dans le traitement de cancers
GB201418713D0 (en) 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
US9517238B2 (en) 2014-11-07 2016-12-13 Children's Hospital Medical Center Compositions and methods for treating allergic inflammation through inhibition of NTRK1
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
AU2015364557C1 (en) 2014-12-18 2021-11-18 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (Trk) inhibitors
WO2016146730A1 (en) 2015-03-19 2016-09-22 Neuheart S.R.L. PEPTIDES HAVING TrkA-RECEPTOR-AGONISTIC ACTIVITY OR HAVING NGF-ANTAGONISTIC ACTIVITY
US20170362327A1 (en) 2015-04-24 2017-12-21 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
EP3506928A2 (en) 2016-09-02 2019-07-10 European Molecular Biology Laboratory Irradiation treatment of neurological sensations by photoablation

Also Published As

Publication number Publication date
CN111788230A (zh) 2020-10-16
JP2021514960A (ja) 2021-06-17
TWI702233B (zh) 2020-08-21
JP7017641B2 (ja) 2022-02-08
US20190263932A1 (en) 2019-08-29
CN111788230B (zh) 2023-11-03
WO2019168730A1 (en) 2019-09-06
EP3759138A1 (en) 2021-01-06
US10618974B2 (en) 2020-04-14
TW201945400A (zh) 2019-12-01

Similar Documents

Publication Publication Date Title
AR114110A1 (es) Anticuerpo anti-trka
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CL2022001271A1 (es) Agonista del receptor glp-1 y uso de este
PH12019502411A1 (en) Cells expressing chimeric activitaing receptors and chimeric stimulating receptors and uses thereof
CO2021008696A2 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
PE20190622A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
AR111362A1 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
EA201791127A1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
PE20180330A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso
CL2016002547A1 (es) Anticuerpos contra her2 biespecíficos
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
AR061568A1 (es) Compuestos
CL2016001028A1 (es) Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh.
MX2020013017A (es) Materiales y metodos para tratar cancer.
CL2008003802A1 (es) Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple.
BR112018067851A2 (pt) composições e métodos para o tratamento de artrite reumatoide
PE20170943A1 (es) Anticuerpos que se unen a ccr6 y sus usos
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение